Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022Ivan Foeldvari, Daniel F. Furst, Susan Maillard et al.|Expert Review of Clinical Immunology|2023Cited by 20
Proposed Response Parameters for <scp>Twelve‐Month</scp> Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus MeetingsIvan Foeldvari, Daniel E. Furst, Kathryn S. Torok et al.|Arthritis Care & Research|2023Cited by 10
AB0966 PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018Ivan Foeldvari, Daniel Furst, Kathryn S. Torok et al.|Annals of the Rheumatic Diseases|2019Cited by 0
AB1717 GUIDANCE FOR STEM CELL THERAPY FOR JUVENILE SYSTEMIC SCLEROSIS PATIENTSIvan Foeldvari, Vanessa Smith, Kathryn S. Torok et al.|Annals of the Rheumatic Diseases|2024Cited by 0
Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022Ivan Foeldvari, Daniel F. Furst, Kathryn S. Torok et al.|UCL Discovery (University College London)|2024Cited by 0